Fortis Healthcare Moat Analysis: Score & Risks
Fortis Healthcare Ltd.
A first-pass moat teardown of Fortis Healthcare Ltd., built from single-pass filing evidence. Free note — provisional, and the full two-pass deep dive may revise it.
First-pass narrow read — primary edge in Network Effects. Provisional, single-pass evidence.
Fortis Healthcare Ltd. scores 4.91 on MoatSCORE 6.0 — a narrow moat in Pharma. This is a first-pass note: the dimensional read and the filing receipts below come from a single GFIP evidence pass, not the full two-pass deep corpus behind our flagship deep dives. Provisional — published free while the deep version is queued.
Seven dimensions of moat
Ordered by contribution. Each dimension carries a verified filing quote, graded [M] mechanism or [O] outcome.
“the total number of new customer touch points has reached 4,370 as of December 31, 2025.”
“I'm pleased to share that financial year '25 has been marked by a significant development. Recently, the company successfully acquired the 'Fortis' brand and trademarks, for a consideration of INR 200 crores.”
“Right now, we are incurring almost Rs. 30 crores to Rs. 50 crores in the legal cost, which is relating to these legacy type of issues.”
“The Company's net debt stood at Rs. 1,694 Crores as on March 31, 2025 compared to Rs. 264 Crores as on March 31, 2024 (net debt to equity of 0.18x versus 0.03x in FY24). Net debt to EBITDA stood at 0.93x as on March 31, 2025 as compared to the 0.17x as on March 31, 2024”
“We have witnessed an occupancy of 64% in Q3 versus 66% in the corresponding quarter, owing to an increase in the operational beds by approx. 100, while the occupied beds remained flat year-on-year.”
D8 rating: ADEQUATE. Not part of the moat score — it governs the cost of equity and the fade window. First-pass; not yet deep-reviewed.
The barrier gate — first-pass
Effective barrier 5 — below 6, so the band is capped narrow. First-pass estimate.
Deep two-pass review. This draft rests on a single GFIP evidence pass; the full 10-year AR + concall corpus may move the read.
The barrier gate. A firmer replication or bypass estimate is the most likely thing to shift the band.
Adverse events. Any governance, regulatory or funding shock captured in D8 could re-rate the fade window.
Where this note fits. This company is one of 509 Indian companies we have scored for moat durability — 370 narrow, 126 narrow-trending-wide, none wide. Every score, dimension by dimension, is free in the Moat Screener.
Member discussion